Cargando…

Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial

While obesity increases colorectal cancer incidence, there are inconsistent results in the prognostic role of obesity or body weight change on survival. This study investigated the prognostic impact of body weight and weight change in stage III or high risk stage II colon cancer patients. We used da...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Dae-Won, Cho, Sooyoung, Shin, Aesun, Han, Sae-Won, Kim, Tae-You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655869/
https://www.ncbi.nlm.nih.gov/pubmed/33173165
http://dx.doi.org/10.1038/s41598-020-76643-9
_version_ 1783608260190797824
author Lee, Dae-Won
Cho, Sooyoung
Shin, Aesun
Han, Sae-Won
Kim, Tae-You
author_facet Lee, Dae-Won
Cho, Sooyoung
Shin, Aesun
Han, Sae-Won
Kim, Tae-You
author_sort Lee, Dae-Won
collection PubMed
description While obesity increases colorectal cancer incidence, there are inconsistent results in the prognostic role of obesity or body weight change on survival. This study investigated the prognostic impact of body weight and weight change in stage III or high risk stage II colon cancer patients. We used data from patients enrolled in the phase III AVANT trial. The AVANT trial investigated the efficacy of adding bevacizumab to standard adjuvant chemotherapy (FOFOX or XELOX). Weight change during the first 6 months of adjuvant chemotherapy was measured. Cox proportional hazard model was used to assess the prognostic influence of body weight and weight change. Among 3451 intention-to-treat population, body weight and weight change was measured in 3449 (99.9%) and 2455 (71.1%) patients, respectively. Among 2455 patients, 651 (26.5%) had weight gain over 5 kg and 179 (7.3%) had weight loss over 5 kg. Weight gain was more frequently observed in Asian and male. Neither baseline BMI nor weight change affected recurrence or survival in the Cox proportional hazard model.
format Online
Article
Text
id pubmed-7655869
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-76558692020-11-12 Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial Lee, Dae-Won Cho, Sooyoung Shin, Aesun Han, Sae-Won Kim, Tae-You Sci Rep Article While obesity increases colorectal cancer incidence, there are inconsistent results in the prognostic role of obesity or body weight change on survival. This study investigated the prognostic impact of body weight and weight change in stage III or high risk stage II colon cancer patients. We used data from patients enrolled in the phase III AVANT trial. The AVANT trial investigated the efficacy of adding bevacizumab to standard adjuvant chemotherapy (FOFOX or XELOX). Weight change during the first 6 months of adjuvant chemotherapy was measured. Cox proportional hazard model was used to assess the prognostic influence of body weight and weight change. Among 3451 intention-to-treat population, body weight and weight change was measured in 3449 (99.9%) and 2455 (71.1%) patients, respectively. Among 2455 patients, 651 (26.5%) had weight gain over 5 kg and 179 (7.3%) had weight loss over 5 kg. Weight gain was more frequently observed in Asian and male. Neither baseline BMI nor weight change affected recurrence or survival in the Cox proportional hazard model. Nature Publishing Group UK 2020-11-10 /pmc/articles/PMC7655869/ /pubmed/33173165 http://dx.doi.org/10.1038/s41598-020-76643-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Lee, Dae-Won
Cho, Sooyoung
Shin, Aesun
Han, Sae-Won
Kim, Tae-You
Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial
title Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial
title_full Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial
title_fullStr Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial
title_full_unstemmed Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial
title_short Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial
title_sort body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the avant trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655869/
https://www.ncbi.nlm.nih.gov/pubmed/33173165
http://dx.doi.org/10.1038/s41598-020-76643-9
work_keys_str_mv AT leedaewon bodymassindexandbodyweightchangeduringadjuvantchemotherapyincoloncancerpatientsresultsfromtheavanttrial
AT chosooyoung bodymassindexandbodyweightchangeduringadjuvantchemotherapyincoloncancerpatientsresultsfromtheavanttrial
AT shinaesun bodymassindexandbodyweightchangeduringadjuvantchemotherapyincoloncancerpatientsresultsfromtheavanttrial
AT hansaewon bodymassindexandbodyweightchangeduringadjuvantchemotherapyincoloncancerpatientsresultsfromtheavanttrial
AT kimtaeyou bodymassindexandbodyweightchangeduringadjuvantchemotherapyincoloncancerpatientsresultsfromtheavanttrial